Metraipolis › archive › dc_41b5b6852832

Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study — Europe PMC PMID:41694229

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41694229
DOI
10.1016/j.bbih.2026.101185
License (as archived)
solo-consultazione
Archived
2026-11-06T10:22:56.781Z
SHA-256 of the archived text
1af835bb189d662b02aa8bbbfbba04f2b0222c006809383f942494c34c5fd87d
Stable URL of this page
https://metraipolis.com/documento/dc_41b5b6852832

How to cite

Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study — Europe PMC PMID:41694229 — Europe PMC (en), https://europepmc.org/article/MED/41694229 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_41b5b6852832 (Metraipolis archive dc_41b5b6852832, sha256 1af835bb189d662b02aa8bbbfbba04f2b0222c006809383f942494c34c5fd87d)
BibTeX
@misc{dc41b5b6852832,
  title = {Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a Mendelian randomization study — Europe PMC PMID:41694229},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41694229},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_41b5b6852832; sha256 1af835bb189d662b02aa8bbbfbba04f2b0222c006809383f942494c34c5fd87d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41694229. Agents can read the archived copy with the MCP tool read_document.